Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.

Document Type

Article

Abstract

Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.

Medical Subject Headings

Alzheimer Disease; Humans; Biomarkers; Positron-Emission Tomography

Publication Date

11-1-2024

Publication Title

Alzheimers Dement

ISSN

1552-5279

Volume

20

Issue

11

First Page

8216

Last Page

8224

PubMed ID

39351838

Digital Object Identifier (DOI)

10.1002/alz.14184

This document is currently not available here.

Share

COinS